Ahmed M. Raslan, M.D. and Jason J Chang, M.D., Assistant Professors of Neurological Surgery and study investigators, performed surgery and the implantation on the T9 neurologically complete patient approximately 36 hours after the injury occurred.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We are pleased that the patient is doing well and wish them continued recovery. We have nine patients enrolled and in follow up and, because we now have over 25 INSPIRE sites open, expect enrollment to increase in the coming months.”
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter.
The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. T
he company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital.
